157 related articles for article (PubMed ID: 22006162)
1. Saturable absorption of sorafenib in patients with solid tumors: a population model.
Hornecker M; Blanchet B; Billemont B; Sassi H; Ropert S; Taieb F; Mir O; Abbas H; Harcouet L; Coriat R; Dauphin A; Goldwasser F; Tod M
Invest New Drugs; 2012 Oct; 30(5):1991-2000. PubMed ID: 22006162
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
4. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).
Hénin E; Blanchet B; Boudou-Rouquette P; Thomas-Schoemann A; Freyer G; Vidal M; Goldwasser F; Tod M
Cancer Chemother Pharmacol; 2014 Feb; 73(2):287-97. PubMed ID: 24253177
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
6. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Semrad TJ; Eddings C; Pan CX; Lau DH; Gandara D; Beckett L; Lara PN
Invest New Drugs; 2012 Oct; 30(5):2001-7. PubMed ID: 22015991
[TBL] [Abstract][Full Text] [Related]
9. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
10. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Arrondeau J; Mir O; Boudou-Rouquette P; Coriat R; Ropert S; Dumas G; Rodrigues MJ; Rousseau B; Blanchet B; Goldwasser F
Invest New Drugs; 2012 Oct; 30(5):2046-9. PubMed ID: 22038662
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
14. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
[TBL] [Abstract][Full Text] [Related]
15. EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
El-Madani M; Colomban O; Tod M; Maillet D; Peron J; Rodriguez-Lafrasse C; Badary OA; Valette PJ; Lefort T; Cassier P; El-Shenawy SM; El-Demerdash E; Hommel-Fontaine J; Guitton J; Gagnieu MC; Ibrahim BM; Barrois C; Freyer G; You B
Future Oncol; 2017 Apr; 13(8):679-693. PubMed ID: 28076966
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Karovic S; Wen Y; Karrison TG; Bakris GL; Levine MR; House LK; Wu K; Thomeas V; Rudek MA; Wright JJ; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
Clin Pharmacol Ther; 2014 Jul; 96(1):27-35. PubMed ID: 24637941
[TBL] [Abstract][Full Text] [Related]
18. Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Liu C; Chen Z; Chen Y; Lu J; Li Y; Wang S; Wu G; Qian F
Mol Pharm; 2016 Feb; 13(2):599-608. PubMed ID: 26709621
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
